Specifically, FAM134B is upregulated in CML promoting cancer cell survival and drug resistance, ultimately associated with poor patient prognosis (Ng et al., 2014). The gene discussed is RETREG1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.